BioInvent International AB
Clinical trials sponsored by BioInvent International AB, explained in plain language.
Biopharmaceutical company focused on antibody-based cancer immunotherapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New cancer drug combo enters first human tests Results expected Jul 2027 (estimated)
-
Experimental antibody trio takes on Hard-to-Treat melanoma
Disease control OngoingThis early-phase trial tests a new experimental antibody called BI-1607 alongside two existing immunotherapies (ipilimumab and pembrolizumab) in 35 people with advanced melanoma that has spread or cannot be removed. The goal is to see if the combination is safe and can shrink tum…
Phase 1/2 • Sponsor: BioInvent International AB • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New cancer drug combo enters first human tests
Disease control OngoingThis early-phase trial is testing an experimental drug called BI-1910, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors (including lung and liver cancers) that have worsened after standard treatments. The main goals are to see if the drug is saf…
Phase 1/2 • Sponsor: BioInvent International AB • Aim: Disease control
Last updated Jun 26, 2026 19:03 UTC